Inactive

The purpose of Amendment 1 (ONE) is to post responses to submitted questions via Attachment 01: Amend 1_RFQ_775N95022R00071_QandA. The NIH is seeking consulting services from senior-level, industry-ex... The purpose of Amendment 1 (ONE) is to post responses to submitted questions via Attachment 01: Amend 1_RFQ_775N95022R00071_QandA. The NIH is seeking consulting services from senior-level, industry-experienced drug discovery and development Key Personnel with expertise in Bioactivity Assay Development to provide leadership and technical guidance to the following programs: Bioactivity Assay Development consulting to support the NIH Blueprint Neurotherapeutics program (BPN). Other NIH neuroscience-focused drug discovery and development programs. The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the National Institutes of Health (NIH), conducting research into the causes, treatment, and prevention of neurological disorders and stroke. The NINDS mission is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. The NIH Blueprint for Neuroscience Research, a consortium of 8 NIH Institutes and Centers that support neuroscience research, established the Blueprint Neurotherapeutics Network (BPN) as a pipeline between the typical endpoint of NIH-funded research and the beginning of industry drug development. The BPN provides neuroscience researchers with funding and access to a full range of industry-style drug development services and expertise. The program is intended for projects requiring medicinal chemistry optimization and contract research organization (CRO) support through Phase I clinical testing. Each project is directed by a Lead Development Team (LDT) composed of the principal investigator (PI), industry consultants hired by NIH, and NIH staff. This team maps out a research strategy, including milestones, and oversees implementation by CROs. Bioactivity and efficacy studies are funded through an award to the PI; other research services can be provided without cost to the PI through NIH contracts.